Navigation Links
Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
Date:9/3/2008

GAITHERSBURG, Md., Sept. 3 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. today announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target. These antibodies were developed in collaboration with the Massachusetts Institute of Technology (MIT) and Panacea has exclusive, worldwide rights to this patent for development of human cancer diagnostics and therapeutics. Panacea is developing PAN-622, an all-human sequence anti-HAAH monoclonal antibody covered under this patent, as a cancer therapeutic antibody drug and anticipates the start of Phase 1 clinical trials in early 2009.

HAAH is a cancer molecular marker that has been detected by immunohistochemical staining in a broad range of cancers; this marker was originally discovered at the Rhode Island Hospital / Brown University. Research done both at Panacea and in collaboration with Brown University / Rhode Island Hospital has established HAAH as an excellent drug target for cancer therapy as well as a marker for cancer diagnosis. HAAH over-expression has been observed in more than twenty different cancers, and HAAH has been shown to be highly specific for cancer and absent in adjacent non-affected tissue as well as tissue from cancer-free individuals. In cancer, HAAH is found on the cell surface and in normal cells found in minute quantities inside the cell. As such, HAAH is an excellent therapeutic target. Panacea has demonstrated the efficacy of PAN-622, an all-human sequence anti-HAAH monoclonal antibody, in animal models of cancer. In these experiments PAN-622 inhibited tumor growth in 90 percent of animals, with 40 percent showing no visible tumor. Tumors did not re-grow beyond the period of drug administration. Due to its all human sequence, PAN-622 is anticipated to have low toxicity in humans. And PAN-622 is currently being manufactured under cGMP at high yields.
'/>"/>

SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
2. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
3. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
4. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
5. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
8. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
9. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
10. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
11. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... HARRISBURG, Pa. , Aug. 31, 2015  The ... held an event today at Gaudenzia Concept 90 to ... the drug overdose crisis in Pennsylvania ... get treatment and focus on recovery through the ... too many Pennsylvanians are dying every day to a ...
(Date:8/31/2015)... DIEGO , Aug. 31, 2015 Regen ... today development of a novel means of delivering ... acid, RGBP-248, to liver tumors utilizing a clinically ... development overcomes previous hurdles with gene silencing therapeutics ... be delivered throughout the whole body.  By utilizing ...
(Date:8/31/2015)... TEL AVIV, Israel , August 31, 2015 ... Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" ... manages and commercializes biomedical innovations in ophthalmology and ... subsidiary, Micromedic Technologies (TASE: MCTC), has identified several ... necrosis of the jawbone in patients treated with ...
Breaking Medicine Technology:Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4
... organizer UBM Live announced strong booking levels ... buyers and sellers of high value chemistry. 248 exhibitors ... takes place from February 19th to 22nd of 2013 ... fine and specialty chemical companies that have signed up ...
... 15, 2012  Adamas Pharmaceuticals, Inc., a privately held ... End-of-Phase 2 meeting with the FDA to discuss ... conducted for the registration of Arimenda (memantine HCl ... once-daily fixed dose combination of extended release memantine ...
Cached Medicine Technology:Strong Booking Levels For Informex 2013 2Strong Booking Levels For Informex 2013 3Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™ 2Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™ 3
(Date:8/31/2015)... ... August 31, 2015 , ... When it comes to undergoing a hair transplant, most patients ... head. Adding more volume to the hair on top of the scalp, as well ... a good amount of donor hair on other areas of their head. , What about ...
(Date:8/31/2015)... ... 2015 , ... India Network Foundation, a non-profit US-based sponsor ... summarizes all available plans, plan maximums, pre-existing condition coverage limits and deductible in ... Network members make an informed decision regarding the care they want for their ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Lisle family law ... William Scott has been nominated by his peers to earn a “Leading Lawyers” distinction. ... percent of attorneys in the state of Illinois. The nomination process is based on ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... is a one-day event geared to patients and family members, medical professionals, and ... and regional mesothelioma experts. The conference is a collaborative effort between the ...
(Date:8/31/2015)... ... 2015 , ... CareSource, a nonprofit Ohio-based health plan, has ... Michael will provide strategic leadership for CareSource’s marketing, branding, corporate communications and media ... contributed to the company’s rapid growth. As the CareSource business model expands to ...
Breaking Medicine News(10 mins):Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:CareSource Names Vice President, Marketing and Corporate Communications 2
... the contraceptive pill because they are worried that they will ... that they have gained weight because of it. However, a ... the combined contraceptive pill does not cause weight increase. ... study of 1,749 women born in 1962, 1972 and 1982 ...
... year, 10,000 pregnant women and up to 200,000 newborn babies ... globe have for years been looking in vain for a ... have found the biochemically weakness of the lethal malaria parasite, ... related malaria. The malaria parasite travels via the spit ...
... Doctors are more apt to recommend a more costly therapy ... life rather than just improve quality, according to a recent ... Using a survey of the decision-making process, authors ... place on quantity of life compared to quality of life ...
... Although traumatic brain injury (TBI) is one of the ... has not been well documented. In a study published in ... Medicine, researchers describe the epidemiology of fatal TBI in ... the first national profile of fatal TBIs occurring in the ...
... Dotinga HealthDay Reporter , MONDAY, June 6 (HealthDay ... violence directly leads to the other, a new study says ... to grow up and abuse their wives and girlfriends. ... different light," said study co-author Jay G. Silverman, an associate ...
... News) -- A new study suggests that cognitive behavioral ... -- may help the depressed in residential treatment programs ... substance disorders and depression fail to receive treatment for ... great," the study authors write. "The interactive nature of ...
Cached Medicine News:Health News:The pill does not lead to weight gain 2Health News:Researchers discover biochemical weakness of malaria parasite -- vaccine to be developed 2Health News:Prolonging life carries more weight 2Health News:Construction industry has highest number of traumatic brain injuries in US workplace 2Health News:Boys Who Bully May Grow Up to Be Abusive Men 2Health News:Cognitive Therapy Helps Depressed Drug Abusers 2
High intensity halogen lamp with built-in, switchable spare. Optical light concentrator to optimize existing light energy....
... biocompatible, flexible, one-piece artificial cornea (keratoprosthesis) designed ... cornea., ,The World Health Organisation (WHO) reports ... million people worldwide, however only 100,000 people ... is due to a combination of inadequate ...
PDA-version of the complete ICD-9 diagnosis codes....
PDA formatted guide containing outlines and detailed information on the diagnosis and treatment of HIV infection and AIDS....
Medicine Products: